Humana Inc.
NYSE:HUM · New York Stock Exchange
+$0.70 today
Vol 3.57M · Avg 1.72M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
6.7%
avg 15.7%
ROIC
3.1%
avg 7.3%
ROA
2.4%
avg 6.0%
Analysis
ROE is currently the strongest return metric at 6.7% versus its period average of 15.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Celeste Mellet | Chief Financial Officer | $8.27M | — | 49 | $39,637.00 | 0.03% |
Japan Mehta | Chief Information Officer | $5.66M | — | 45 | $17,176.00 | 0.01% |
James A. Rechtin | President, Chief Executive Officer & Director | $4.89M | — | 55 | $63,938.00 | 0.05% |
Michelle O'Hara | Chief Human Resources Officer | $4.08M | — | 50 | $20,026.00 | 0.02% |
Bruce Dale Broussard | Strategic Advisor | $4.06M | — | 64 | $0.00 | <0.01% |
Sanjay K. Shetty | President of CenterWell | $2.09M | — | 52 | $22,088.00 | 0.02% |
Joseph C. Ventura | Chief Legal Officer | $840,359.00 | — | 49 | $27,405.00 | 0.02% |
John-Paul W. Felter | Senior Vice President, Chief Accounting Officer & Controller | — | — | 42 | $7,568.00 | <0.01% |
Bobby Mukundan | Senior Vice President & Chief Technology Officer | — | — | — | — | — |
Lisa Stoner | Vice President of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$150,016.05
Sells
0
$0.00
Net Sentiment
+$150,016.05
Net buying
Most Active
Shetty Sanjay K
1 transactions
Analysis
Insiders reported 1 buys worth $150,016.05 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $150,016.05. Shetty Sanjay K was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +4.2% | +10.1% (15yr)5 analysts |
| Revenue | N/A | N/A | +11.5% | +9.2% (15yr)7 analysts |
| Net Income | N/A | N/A | +1.5% | +8.5% (15yr)7 analysts |
| EBIT | N/A | N/A | +4.4% | +7.0% (15yr)7 analysts |
Analysis
Recent growth has been strongest in Revenue at +11.5% over three years. Forward estimates point to EPS at +10.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Haleon plc
NYSE:HLN
$39.54B
Agilent Technologies, Inc.
NYSE:A
$35.98B
Alcon Inc.
NYSE:ALC
$31.54B
Centene Corporation
NYSE:CNC
$30.28B
BeOne Medicines Ltd.
NASDAQ:ONC
$28.67B
IQVIA Holdings Inc.
NYSE:IQV
$27.97B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$27.91B
ResMed Inc.
NYSE:RMD
$27.23B
Mettler-Toledo International Inc.
NYSE:MTD
$23.18B
Insmed Incorporated
NASDAQ:INSM
$20.59B
Who manages HUM?
Humana Inc. (HUM) lists 10 active executives. The top listed executive is James A. Rechtin, President, Chief Executive Officer & Director.
Are HUM insiders buying or selling?
Recent insider activity shows net selling of $6.15M.
Explore More
Continue the stock analysis
Jump to another research area for this company.